Company News: Page (1) of 1 - 06/13/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook

Editas Medicine to Participate in The JMP Securities Life Sciences Conference

(June 13, 2018)

CAMBRIDGE, Mass., June 13, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will participate in a panel and host investor meetings at the JMP Securities Life Sciences Conference in New York on Wednesday, June 20, 2018.  Details of the panel are as follows:

Panel: Gene Editing – From Science to Reality
Date: Wednesday, June 20, 2018
Time: 8:00 a.m.
Location: St. Regis Hotel, New York                          

About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.

Contacts



Media:
Cristi Barnett   ?
(617) 401-0113
[email protected]

Investors:
Mark Mullikin
(617) 401-9083
[email protected]


Page: 1


Related Keywords:

-->

Our Privacy Policy --- @ Copyright, 2015 Digital Media Online, All Rights Reserved